Intellipharmaceutics International Inc.
IPCIF · OTC
8/31/2023 | 5/31/2023 | 2/28/2023 | 11/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -85.7% | 47.1% | 999.5% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | -1,171.5% | 93% | 84.2% | 100% |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $0 |
| Operating Income | -$2 | -$0 | -$0 | -$0 |
| % Margin | -2,601% | -6.5% | -92.4% | -1,548.3% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$0 | -$0 | -$1 |
| % Margin | -2,749.2% | -11.3% | -109% | -2,947% |
| EPS | -0.057 | -0.002 | -0.011 | -0.026 |
| % Growth | -3,468.8% | 85% | 59.5% | – |
| EPS Diluted | -0.057 | -0.002 | -0.011 | -0.026 |
| Weighted Avg Shares Out | 33 | 33 | 33 | 33 |
| Weighted Avg Shares Out Dil | 33 | 33 | 33 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | $0 | -$0 | -$0 |
| % Margin | -2,541.9% | 1.9% | -79.9% | -1,374.4% |